Leite, Â., Dinis, M. A. P., Sequeiros, J., & Paúl, C. (2017). Illness representations, knowledge and motivation to perform presymptomatic testing for late-onset genetic diseases. Psychology, Health and Medicine, 22(2), 244 - 249.

Moniz, T., Leite, Â., Silva, T., Gameiro, P., et al. (2017). The influence of functional groups on the permeation and distribution of antimycobacterial rhodamine chelators. Journal of Inorganic Biochemistry, 175, 138 - 147.

Leite, Â., Dinis, M. A. P., Sequeiros, J., & Paúl, C. (2017). Motivation to perform presymptomatic testing in portuguese subjects at-risk for late-onset genetic diseases. Interdisciplinaria, 34(1), 125 - 140.

Lêdo, S., Leite, Â., Souto, T., Dinis, M. A. P., & Sequeiros, J. (2017). Pre-symptomatic testing for neurodegenerative disorders: Middle- to long-term psychopathological impact. Psicothema, 29(4), 446 - 452.

Leite, Â., Leite, F., & Dinis, M. A. P. (2017). Subjects at Risk for Genetic Late-Onset Neurological Diseases: Objective Knowledge. Public Health Genomics, 20(3), 158 - 165.

Lêdo, S., Leite, Â., Souto, T., Dinis, M. A., & Sequeiros, J. (2016). Depression as the Middle-and Long-Term Impact for Pre-Symptomatic Testing of Late-Onset Neurodegenerative Disorders. Temas em Psicologia, 24(2), 579 - 594.

Lêdo, S., Leite, Â., Souto, T., Dinis, M. A., & Sequeiros, J. (2016). Mid-and long-term anxiety levels associated with presymptomatic testing of Huntington?s disease, Machado-Joseph disease, and familial amyloid polyneuropathy. Revista Brasileira de Psiquiatria, 38(2), 113 - 120.

Leite, Â., Dinis, M. A. P., Sequeiros, J., & Paúl, C. (2016). Subjects At-Risk for Genetic Diseases in Portugal: Illness Representations. Journal of Genetic Counseling, 25(1), 79 - 89.

Leite, Â., Dinis, M. A. P., Sequeiros, J., & Paúl, C. (2015). Subjects At-Risk for Genetic Diseases in Portugal: Illness Representations. Journal of Genetic Counseling.

Rolim, L., Leite, Â., Lêdo, S., Paneque, M., et al. (2006). Psychological aspects of pre-symptomatic testing for Machado-Joseph disease and familial amyloid polyneuropathy type I. Clinical Genetics, 69(4), 297 - 305.